Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Safety, Tolerability, and Efficacy Study of Veligrotug, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor in Subjects With Thyroid Eye Disease

Next Previous
Trial Profile

A Safety, Tolerability, and Efficacy Study of Veligrotug, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor in Subjects With Thyroid Eye Disease

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 07 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Veligrotug (Primary) ; Sodium chloride
  • Indications Graves ophthalmopathy
  • Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
  • Acronyms THRIVE
  • Sponsors Viridian Therapeutics

Most Recent Events

  • 01 Sep 2026 Results published in the Ophthalmology
  • 26 Jun 2026 According to a Viridian Therapeutics media release, company announced that the U.S. Food and Drug Administration (FDA) has approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED). Company on track for a biologics license application (BLA) submission in Q1 2027.
  • 22 Dec 2025 According to a Viridian Therapeutics media release, based on results form trial THRIVE and THRIVE-2, the company also plans to submit a Marketing Authorization Application to the European Medicines Agency in the first quarter of 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top